Live feed07:36:12·556dANALYSTRatingvia QuantisnowRobert W. Baird initiated coverage on Dyne Therapeutics with a new price targetByQuantisnow·Wall Street's wire, on your screen.DYN· Dyne Therapeutics Inc.Health CareOriginal source